Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:G01N AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/186053COMPOUNDS FOR TREATING OR PREVENTING A CORONAVIRIDAE INFECTION & METHODS AND USES FOR ASSESSING THE OCCURRENCE OF A CORONAVIRIDAE INFECTION
WO 23.09.2021
Int.Class A61K 31/47
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
Appl.No PCT/EP2021/057123 Applicant ABIVAX Inventor TAZI, Jamal
The present invention relates to the treatment or prevention of a Coronaviridae infection, and conditions related thereto; in particular a Coronaviridae infection in humans. In particular, the invention relates to compounds, pharmaceutical compositions and medicaments for treating and/or preventing a Coronaviridae infection and/or its longterm consequences. The invention further relates to uses and methods for assessing a Coronaviridae infection or the efficacy of a treatment of such infections.
2.WO/2021/204770PRO-ADRENOMEDULLIN FOR PROGNOSING DISEASE PROGRESSION IN SEVERE ACUTE RESPIRATORY SYNDROME (SARS)
WO 14.10.2021
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
Appl.No PCT/EP2021/058885 Applicant B.R.A.H.M.S GMBH Inventor EBMEYER, Stefan
The invention relates to a method for prognosing disease progression in a patient that has or is at risk of developing a severe acute respiratory syndrome (SARS), wherein the method comprises determining a level of pro-adrenomedullin (proADM) or fragment(s) thereof in a sample from the patient, wherein said level indicates the severity of SARS progression. The method is in some embodiments configured for use when a patient exhibits symptoms of a severe acute respiratory syndrome (SARS), a patient exhibits symptoms of infection with a SARS-virus, the patient is infected with a SARS-virus, such as a SARS-coronavirus, such as SARS-CoV2.
3.3101131COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CORONAVIRUS INFECTION - SARS­COV-2 VACCINES
CA 31.07.2021
Int.Class C12N 15/15
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
12Genes encoding animal proteins
15Protease inhibitors, e.g. antithrombin, antitrypsin, hirudin
Appl.No 3101131 Applicant JANSSEN PHARMACEUTICALS, INC. Inventor

P217625CA00 CR U6043CAN P1
- 269 -
COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CORONAVIRUS
INFECTION - SARS-COV-2 VACCINES
Abstract
The invention relates to immunogenic compositions and vaccines containing a
coronavirus
(e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein
or a
polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV;
SARS-CoV-
2)) protein and uses thereof. The invention also provides methods of treating
and/or
preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2))
infection
by administering an immunogenic composition or vaccine to a subject (e.g., a
human). The
invention also provides methods of detecting and/or monitoring a protective
anti-
coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody
response (e.g.,
anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response,
e.g., anti-
Spike antibody response, e.g., anti-Spike neutralizing antibody response). The
present
invention relates to isolated nucleic and/or recombinant nucleic acid encoding
a
coronavirus S protein, in particular a SARS-CoV-2 S protein, and to the
coronavirus S
proteins, as well as to the use of the nucleic acids and/or proteins thereof
in vaccines.
<1093966>
Date Recue/Date Received 2020-11-28

4.10948490Severe acute respiratory syndrome (SARS)—associated coronavirus diagnostics
US 16.03.2021
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
Appl.No 16944649 Applicant INSTITUT PASTEUR Inventor Sylvie Van Der Werf

The invention relates to the diagnosis of a SARS-associated coronavirus, such as a SARS CoV-2 infection and SARS-CoV infection, using the SARS-CoV and SARS-CoV-2 nucleocapsid proteins and antibodies binding to these proteins. The invention encompasses reagents, methods and kits for the detection of a SARS-associated coronavirus.

5.20040235047Methods for treatment of severe acute respiratory syndrome (SARS)
US 25.11.2004
Int.Class G01N 33/53
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
Appl.No 10441059 Applicant Wyeth Holdings Corporation Inventor Siber George R.

Compositions and methods for treating Severe Acute Respiratory Syndrome (SARS) are disclosed herein. Inhibitors of SARS-associated inflammatory cytokines are provided herein for use in treating SARS, including SARS-associated coronavirus (SARS-CoV) infection. Inhibitors of TNF are disclosed herein, as is the use of said inhibitors for treating SARS, including SARS-CoV. Methods of identifying and screening for said inhibitors are also provided.

6.WO/2021/186190CORONAVIRUS ANTIBODY
WO 23.09.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/GB2021/050685 Applicant IMPERIAL COLLEGE INNOVATIONS LIMITED Inventor XU, Xiao-Ning
An antibody or antigen-binding fragment thereof is described which binds to the spike protein S2 domain of severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome-related coronavirus (MERS-CoV) and/ or severe acute respiratory syndrome coronavirus 2 (SARS CoV-2). The antibodies can be used in the diagnosis and treatment of coronavirus infection. The invention extends to compositions comprising the antibodies, including pharmaceutical compositions, diagnostic compositions, and kits. The invention also extends to methods of making and using the antibodies, for example in the diagnosis and therapy of coronavirus infections.
7.20210293827METHODS OF DIAGNOSING RISK OF SERIOUS SYMPTOMS FROM COVID-19 INFECTION
US 23.09.2021
Int.Class G01N 33/68
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
Appl.No 16913840 Applicant Henry Winchester Inventor Henry Winchester

Provided herein are methods for reducing risk of severe symptoms and outcomes associated with Coronavirus Disease 2019 (COVID-19) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection by measuring levels of interleukin 6 (IL-6), IL8, IL22, and serum ferritin in a subject. Also provided are methods for treating a subject exposed to or at elevated risk of expose to SARS-CoV-2 based on levels of IL6, IL8, IL22, and ferritin in the serum of the subject.

8.WO/2021/205455SARS-COV2 CORONAVIRUS RECONSTITUTED RBM AND USES THEREOF
WO 14.10.2021
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/IL2021/050402 Applicant RAMOT AT TEL-AVIV UNIVERSITY LTD. Inventor GERSHONI, Jonathan M.
The present invention relates to vaccines and therapeutic compositions targeted at coronaviruses, specifically, the Severe Acute Respiratory Syndrome coronavirus 2 (SARS CoV2). More specifically, the invention provides reconstituted Receptor Binding Motif (RBM) of a Spike protein of the SARS CoV2, Receptor Binding domains (RBDs), and spike proteins comprising the reconstituted RBMs or τ -linkers, compositions, vaccines, therapeutic and diagnostic methods and uses thereof.
9.WO/2008/045120TRANSGENIC MOUSE LINES EXPRESSING HUMAN ACE2 AND USES THEREOF
WO 17.04.2008
Int.Class C12N 15/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
Appl.No PCT/US2007/000744 Applicant THE BOARD OF TRUSTEES OF THE UNIVERSITY OF TEXAS SYSTEM AND CHAN ET AL Inventor CHAN, Teh-Sheng
Animal models for severe acute respiratory syndrome (SARS)-coronavirus infection of humans are needed to elucidate SARS pathogenesis and develop vaccines and antivirals. Transgenic mice were developed expressing human angiotensin-converting enzyme 2, a functional receptor for the virus, under the regulation of a global promoter. A transgenic lineage, designated AC70, was among the best characterized against SARS coronavirus infection, showing weight loss and other clinical manifestations before reaching 100% mortality within 8 days after intranasal infection. High virus titers were detected in the lungs and brains of transgene-positive mice on days 1 and 3 after infection. Inflammatory mediators were also detected in these tissues, coinciding with high levels of virus replication. In contrast, infected transgene-negative mice survived without showing any clinical illness. The severity of the disease developed in these transgenic mice, AC70 in particular, makes these mouse models valuable not only for evaluating the efficacy of antivirals and vaccines, but also for studying SARS coronavirus pathogenesis and infection by other coronaviruses utilizing human ACE2 for viral entry into cells.
10.3889604SEVERE ACUTE RESPIRATORY SYNDROME (SARS) - ASSOCIATED CORONAVIRUS DIAGNOSTICS
EP 06.10.2021
Int.Class G01N 33/53
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
Appl.No 20189060 Applicant PASTEUR INSTITUT Inventor VAN DER WERF SYLVIE
The invention relates to the diagnosis of a SARS-associated coronavirus, such as a SARS CoV-2 infection and SARS-CoV infection, using the SARS-CoV and SARS-CoV-2 nucleocapsid proteins and antibodies binding to these proteins. The invention encompasses reagents, methods and kits for the detection of a SARS-associated coronavirus.